Repare Therapeutics Inc. (RPTX): Price and Financial Metrics

Repare Therapeutics Inc. (RPTX): $3.65

0.25 (-6.41%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add RPTX to Watchlist
Sign Up

RPTX Price/Volume Stats

Current price $3.65 52-week high $13.85
Prev. close $3.90 52-week low $3.08
Day low $3.61 Volume 94,300
Day high $3.98 Avg. volume 147,896
50-day MA $5.82 Dividend yield N/A
200-day MA $7.33 Market Cap 135.05M

RPTX Stock Price Chart Interactive Chart >


Repare Therapeutics Inc. (RPTX) Company Bio


Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.


RPTX Latest News Stream


Event/Time News Detail
Loading, please wait...

RPTX Latest Social Stream


Loading social stream, please wait...

View Full RPTX Social Stream

Latest RPTX News From Around the Web

Below are the latest news stories about REPARE THERAPEUTICS INC that investors may wish to consider to help them evaluate RPTX as an investment opportunity.

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

Yahoo | November 20, 2023

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

CAMBRIDGE, Mass. & MONTREAL, November 15, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467.

Yahoo | November 15, 2023

Repare Therapeutics Inc. (NASDAQ:RPTX) most popular amongst private equity firms who own 33% of the shares, institutions hold 28%

Key Insights The considerable ownership by private equity firms in Repare Therapeutics indicates that they collectively...

Yahoo | November 12, 2023

These Biotech Stocks Could Double Your Money, According To Analysts

The biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate. While the pandemic-relate

Yahoo | November 9, 2023

Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline Progress

Initial Positive Data from MYTHIC Trial and Preclinical Program Updates

Yahoo | November 9, 2023

Read More 'RPTX' Stories Here

RPTX Price Returns

1-mo -31.00%
3-mo -42.97%
6-mo -24.90%
1-year -59.76%
3-year -89.16%
5-year N/A
YTD -50.00%
2023 -50.37%
2022 -30.25%
2021 -38.51%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!